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Luminal Ca2 +-binding proteins play a central role in mediating between Ca2 +-uptake and Ca2 +-release during the excitation–
contraction–relaxation cycle in muscle fibres. In the most commonly inherited neuromuscular disorder, Duchenne muscular dystrophy
(DMD), the reduced expression of key Ca2 +-binding proteins causes abnormal Ca2 +-buffering in the sarcoplasmic reticulum (SR) of
skeletal muscle. The heart is also affected in dystrophinopathies, as manifested by the pathological replacement of cardiac fibres by
connective and fatty tissue. We therefore investigated whether similar changes occur in the abundance of luminal Ca2 +-regulatory
elements in dystrophin-deficient cardiac fibres. Two-dimensional immunoblotting of total cardiac extracts was employed to
unequivocally determine potential changes in the expression levels of SR components. Interestingly, the expression of the histidine-
rich Ca2 +-binding protein was increased in the dystrophic heart. In contrast, the major Ca2 +-reservoir protein of the terminal cisternae,
calsequestrin (CSQ), and the Ca2 +-shuttle and ion-binding protein of the longitudinal tubules, sarcalumenin, were drastically reduced in
cardiac mdx fibres. This result agrees with the recently reported decrease in the Ca2 +-release channel and Ca2 +-ATPase in the mdx
heart. Abnormal Ca2 +-handling appears to play a major role in the molecular pathogenesis of the cardiac involvement in X-linked
muscular dystrophy.
D 2004 Elsevier B.V. All rights reserved.Keywords: Muscular dystrophy; Cardiomyopathy; mdx; Dystrophin; Calsequestrin; Sarcalumenin
1. Introduction extracellular matrix [6], loss of this complex impairs theThe most common gender-specific genetic disease in
humans is represented by X-linked Duchenne muscular
dystrophy (DMD), a neuromuscular disorder affecting
skeletal muscles, the heart and the nervous system to a
varying degree [1–3]. Primary genetic abnormalities in the
DMD gene lead to a deficiency in the membrane cyto-
skeletal protein dystrophin [4] and a significant reduction
in a surface-associated glycoprotein complex [5]. Since
the dystrophin–glycoprotein complex stabilises the fibre
periphery in normal muscle providing a trans-sarcolemmal
linkage between the actin membrane cytoskeleton and the0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.04.002
Abbreviations: CSQ, calsequestrin; DMD, Duchenne muscular dystro-
phy; Dp427, full-length dystrophin isoform of 427 kDa; HRCBP, histidine-
rich calcium binding protein; mdx, X-linked muscular dystrophy mouse;
SAR, sarcalumenin; SR, sarcoplasmic reticulum
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E-mail address: kay.ohlendieck@may.ie (K. Ohlendieck).integrity of the sarcolemma [7]. The calcium hypothesis of
muscular dystrophy assumes that a weakened plasma
membrane structure renders the muscle surface more
susceptible to microscopical membrane rupturing [8].
During the natural processes of surface membrane reseal-
ing, Ca2 +-leak channels are introduced into the dystrophic
sarcolemma causing increased cytosolic Ca2 +-levels in
dystrophin-deficient muscle fibres [9]. A recent report by
Mallouk et al. [10] suggests that the Ca2 +-elevations
occur not throughout the sarcoplasm but are located near
the sarcolemma. The rise in the cytosolic Ca2 +-concen-
tration contributes to a pathophysiological cycle of en-
hanced protease activity and subsequent Ca2 +-leak
channel activation [9].
Since changes in Ca2 +-homeostasis may trigger severe
muscle fibre damage in neuromuscular disorders, the fate
of the Ca2 +-regulatory apparatus has been the subject of
numerous investigations into the pathology of muscular
dystrophy [8–13]. Comparative equilibrium dialysis
revealed that the overall Ca2 +-buffering capacity of the
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approximately 20% [12]. It is believed that the drastic
reduction in the calsequestrin (CSQ)-like proteins CLP-
150, CLP-170 and CLP-220 [12] represents impaired
CSQ clustering [14]. This may lead to changes in the
co-operative kinetics within CSQ clusters causing reduced
ion-binding that may contribute to a decreased luminal
SR Ca2 +-buffering capacity. In addition, the expression of
the Ca2 +-shuttle protein sarcalumenin (SAR) is approxi-
mately 70% lower in mdx fibres as compared to normal
skeletal muscle [13]. Pathophysiologically, the reduced
ion-binding capacity of the luminal SR probably amplifies
elevated free cytosolic Ca2 +-levels and thereby accelerates
the dystrophic protein degradation process in skeletal
muscle fibres.
Besides severe skeletal muscle degeneration [15], the
clinical progression of X-linked muscular dystrophy also
encompasses impaired cardiac function in the majority of
patients [16]. Since cardiomyopathy is the cause of death
in a significant proportion of DMD cases [2], it is of
central importance to understand the pathobiochemical
pathways leading to dystrophic abnormalities in the heart
[17]. A widely employed animal model of DMD is
represented by the mdx mouse [18], which is missing
the full-length Dp427 isoform of dystrophin due to a
spontaneous point mutation in exon 23 [19]. Although the
mdx heart is not a perfect replica of the cardiac involve-
ment in the human disease [2], its dystrophic phenotype
is clearly of clinical relevance [20]. The mdx heart
exhibits markedly altered contractile properties [21] and
displays necrotic changes and inflammation [22], and mdx
mice show an abnormal electrocardiogram [23]. Thus, the
dystrophic phenotype of the mdx heart represents a
suitable DMD model to investigate potential changes in
Ca2 +-handling proteins due to a deficiency in dystrophin.
The 2D immunoblotting analysis of total cardiac mdx
extracts presented here demonstrates a reduced expression
of two major luminal Ca2 +-binding proteins of the SR,
CSQ and SAR. This suggests that the calcium hypothesis
of muscular dystrophy can, at least partially, be extrapo-
lated from skeletal muscle to cardiac fibres.2. Materials and methods
2.1. Materials
Protease inhibitors were purchased from Roche Diag-
nostics GmbH (Mannheim, Germany). Chemilumines-
cence substrates were obtained from Perbio Science UK
(Tattenhall, Chesire). Immobilised pH-gradient (IPG)-
strips of pH 3–10 and IPG buffer of pH 3–10 were
obtained from Amersham Pharmacia Biotech (Little Chal-
font, Buckinghamshire, UK). Primary antibodies were
obtained from Novacastra Laboratories, Newcastle upon
Tyne, UK (mAb DYS-2 to the carboxy-terminus of thedystrophin isoform Dp427), Affinity Bioreagents, Golden,
CO, USA (mAb XIIC4 to sarcalumenin and pAb to
cardiac calsequestrin), Sigma Chemical Company, Poole,
Dorset, UK (pAb to laminin), and Upstate Biotechnolo-
gy, Lake Placid, NY, USA (mAb C464.6 to the a1-
subunit of the Na+/K+-ATPase and mAb VIA41 to a-
dystroglycan). Antibodies to the histine-rich Ca2 +-binding
protein HRCBP (histidine-rich calcium binding protein)
were a generous gift from Dr. Sandra L. Hofmann
(Human Center for Therapeutic Oncology Research,
Dallas, TX, USA). Peroxidase-conjugated secondary anti-
bodies were purchased from Chemicon International
(Temecula, CA, USA). Ultrapure Protogel acrylamide
stock solutions were obtained from National Diagnostics
(Atlanta, GA, USA). Protran nitrocellulose membranes
were from Schleicher and Schuell (Dassel, Germany). All
other chemicals used were of analytical grade and
purchased from Sigma.
2.2. Preparation of cardiac membrane vesicles
All preparative steps were performed at 0–4 jC and
all isolation buffers contained a mixture of protease
inhibitors (0.2 mM Pefabloc, 1.4 AM pepstatin A, 0.3
AM E-64, 1 AM leupeptin, 1 mM EDTA, 0.5 AM soybean
trypsin inhibitor). Hearts from 8- and 18-week-old normal
control C57BL/10 mice and age-matched mdx mice of the
Dmdmdx strain (Jackson Laboratory, Bar Harbor, Maine,
USA) were obtained through the Biomedical Facility of
the National University of Ireland, Dublin. For 1D im-
munoblotting, a crude membrane fraction was prepared
from normal and dystrophic heart, as well as skeletal
muscle specimens, by a previously established protocol
[24]. Membranes were resuspended at a protein concen-
tration of 10 mg/ml and used immediately for gel
electrophoretic separation.
2.3. Immunoblotting
For standard 1D gel electrophoresis and second-di-
mension separation, a Mini-MP3 electrophoresis system
from Bio-Rad Laboratories (Hempel Hempstead, Herts-
fortshire, Herts, UK) was employed. The gel electropho-
retic separation of microsomal membrane proteins was
carried out under reducing conditions in the presence of
sodium dodecyl sulfate [25], using 7% (w/v) polyacryl-
amide gels run for 280 Vh with 25 Ag protein per lane.
Subsequent immunoblotting was performed according to
Towbin et al. [26] using a Bio-Rad Mini-MP3 blotting
cell system (Bio-Rad Laboratories). Antibody incubation
and visualization of immuno-decorated protein bands by
enhanced chemiluminescence (ECL) was carried out as
previously described in detail [27]. Densitometric scan-
ning of ECL-blots was performed on a Molecular Dy-
namics 300S computing densitometer (Sunyvale, CA)
using ImageQuant V3.0 software. Statistical analysis
Fig. 1. Comparative one-dimensional immunoblot analysis of normal and
dystrophic mdx skeletal muscle and heart membranes. Shown are
immunoblots of normal (lane 1) and dystrophic mdx (lane 2) membranes
isolated from skeletal muscle (A, B) or heart (C–H) homogenates. Blots
were labelled with antibodies to the Dp427 isoform of dystrophin (A, C),
laminin (LAM) (B, D), a-dystroglycan (a-DG) (E), the histidine-rich Ca2 +-
binding protein (HRCBP) (F), sarcalumenin (SAR) (G) and calsequestrin
(CSQ) (H). The position of immuno-decorated bands is marked by
arrowheads.
Fig. 2. Two-dimensional immunoblot analysis of luminal Ca2 +-binding
proteins in 8 week old normal and mdx heart. Shown are silver-stained gels
(A, B) and corresponding immunoblots (C–H) of total extracts from 8-
week (wk)-old normal (A, C, E, G) and dystrophic mdx (B, D, F, H) cardiac
muscle. Immunoblots were labelled with antibodies to the histidine-rich
Ca2 +-binding protein (HRCBP) (C, D), calsequestrin (CSQ) (E, F) and
sarcalumenin (SAR) (G, H). The position of immuno-decorated protein dots
is marked by arrowheads. The pH values of the first dimension gel system
and molecular mass standards (in kDa) of the second dimension are
indicated on the top and on the left of the panels, respectively.
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San Diego, CA, USA) was used to perform t-test for
unpaired observations.
2.4. 2D-electrophoretic analysis of total cardiac extracts
Prior to isoelectric focusing, whole hearts were ground
to a fine powder using liquid nitrogen and subsequently
solubilized in lysis buffer (9.5 M urea, 4% w/v CHAPS,
0.5% v/v carrier ampholytes 3–10, 100 mM DTT). The
solution was supplemented with a freshly prepared prote-
ase inhibitor cocktail (0.2 mM Pefabloc, 1.4 AM pepstatin,
0.15 AM aprotinin, 0.3 AM E-64, 1 AM leupeptin, 0.5 mM
soybean trypsin inhibitor and 1 mM EDTA) in order to
prevent protein degradation. In addition, to reduce exces-
sive viscosity of the extract due to DNA, 2 Al of DNase I
(200 units) was added per 100-Al lysis buffer. After
incubation for 3 h at 20 jC, the suspension was centri-
fuged for 20 min at 20,000 g, and the supernatant diluted
in lysis buffer to achieve a final protein concentration of
50 Ag protein per strip for silver staining or subsequent
immunoblotting experiments. Isoelectric focusing and sep-
aration in the second dimension was perfomed by estab-
lished techniques [13]. Immunoblotting and silver stainingof 2D gels was carried out as previously described in detail
[28].3. Results
3.1. Characterisation of cardiac mdx membranes
Prior to the 2D gel electrophoretic and immunoblot
analysis of total cardiac extracts from normal and mdx
tissues, the mutant status of the animal model was evaluat-
ed. In contrast to laminin (Fig. 1B and D), the Dp427
isoform of both skeletal and cardiac muscle dystrophin was
found to be absent from mdx microsomal membrane prep-
arations (Fig. 1A and C). As illustrated in Fig. 1E, the
expression of a representative of the dystrophin-associated
glycoprotein complex, a-dystroglycan, was drastically re-
duced in dystrophic mdx cardiac preparations. The initial
1D immunoblotting of luminal Ca2 +-regulatory proteins
revealed on the one hand a potential increase in the
histidine-rich Ca2 +-binding protein HRCBP, and on the
Fig. 3. Two-dimensional immunoblot analysis of calsequestrin in 18-week-
old normal and mdx heart. Shown are silver-stained gels (A, B) and
corresponding immunoblots (C–F) of total extracts from 18-week (wk)-old
normal (A, C, E) and dystrophic mdx (B, D, F) cardiac muscle.
Immunoblots were labelled with antibodies to calsequestrin (CSQ) (C, D)
and the a1-subunit of the Na
+/K+-ATPase (NKA) (E, F). The position of
immuno-decorated protein dots is marked by arrowheads. The pH values of
the first dimension gel system and molecular mass standards (in kDa) of the
second dimension are indicated on the top and on the left of the panels,
respectively.
Fig. 4. Changed expression profiles of luminal Ca2 +-binding proteins in
the dystrophic mdx heart. Shown is the graphical presentation of the
immunoblot analysis (meansF S.D.; n= 5; *P< 0.05; **P< 0.01) of 8-
and 18-week-old normal and dystrophic mdx cardiac preparations. Panels
A to E represent the dystrophin isoform Dp427, sarcalumenin,
calsequestrin, the histidine-rich Ca2 +-binding protein and the Na+/K+-
ATPase, respectively.
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constituent CSQ and the Ca2 +-shuttle element SAR (Fig.
1F–H).
3.2. 2D immunoblot analysis of luminal Ca2+-binding
proteins in cardiac mdx tissue
For the comparative analysis of total cardiac extracts,
we employed a 2D immunoblotting approach in this
study. As illustrated in Fig. 2, the luminal Ca2 +-binding
proteins HRCBP, CSQ and SAR exhibited distinct differ-
ences in their expression profile in 8-week-old dystrophic
hearts as compared to age-matched normal cardiac tissue.
In contrast, the silver staining pattern of 2D-separated
cardiac muscle proteins did not reveal dramatic changes
in the overall expression of abundant protein species (Fig.
2A and B). Certain spots of low density showed a
modified intensity in diseased preparations versus normal
controls. A future proteomics-based approach using mass
spectroscopical identification methodology might be use-
ful in the evaluation of these global changes in protein
expression. However, current proteomic tools often miss
the proper identification of integral proteins, very large
proteins, aggregated assemblies, components with a very
basic pI-value and/or proteins of low abundance. The
background staining due to highly abundant proteins,such as myosin and actin in muscle preparations, can
also diminish the accuracy of the mass spectroscopic
analysis. This still allows immunoblotting with highly
specific antibodies a central place in the list of reliable
and versatile biochemical detection techniques. Interest-
ingly, our immunoblotting approach detected molecular
species by antibody decoration that did not correlate with
distinct silver-stained dots in the 2D gel (Fig. 2C–H).
While HRCBP exhibited a basic pI-value of approximate-
ly pH 8 to 9, the two other luminal Ca2 +-binding proteins
showed a more acid pI-value in the pH 4 to 6 range. The
relative molecular masses of the three immuno-decorated
protein dots were approximately 130, 63 and 160 kDa for
HRCBP, CSQ and SAR, respectively. Immuno-decoration
clearly showed an increase in HRCBP expression and a
decreased density of CSQ and SAR in dystrophic mdx
heart preparations as compared to dystrophin-containing
controls. Similar findings were obtained from older mdx
heart preparations. The representative immunoblot analy-
sis of cardiac CSQ in Fig. 3C and D demonstrates the
reduction of this terminal cisternae marker in 18-week-old
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staining pattern of Fig. 3A and B underlines the impor-
tance of this finding. Deficiency in dystrophin does not
seem to cause a massive alteration in the expression
profile of abundant cardiac proteins but has distinct
effects on a subset of components. For control purposes
and to show that equal loading conditions were employed,
the comparative expression of the Na+/K+-ATPase is
shown in Fig. 3E and F. Apparently, this surface ion
pump is not drastically affected in its abundance in
dystrophic heart.
3.3. Reduced calsequestrin and sarcalumenin expression in
dystrophic heart muscle
The graphical presentation of our immunoblot analysis of
luminal SR Ca2 +-binding proteins summarises the major
findings of this report. In both mdx age groups studied, the
deficiency in cardiac dystrophin (Fig. 4A) clearly resulted in
a reduced expression of SAR (Fig. 4B) and CSQ (Fig. 4C)
to a varying degree. In contrast, the HRCBP was increased
in both 8- and 18-week-old dystrophic hearts (Fig. 4D).
Immunoblotting of younger heart muscle specimens did not
result in sufficient immuno-decoration above background
staining (not shown) and was therefore not further pursued.
The expression levels of the surface Na+/K+-ATPase were
not drastically changed in the mdx heart preparations as
compared to normal age-matched hearts (Fig. 4E).Fig. 5. Overview of abnormal Ca2 +-handling in the dystrophic heart. Shown
excitation–contraction (EC) coupling and fibre relaxation. This includes the transv
the RyR2 isoform of the sarcoplasmic reticulum (SR) ryanodine receptor Ca2 +-rele
Ca2 +-induced Ca2 +-release (CICR) mechanism. Shown are the luminal Ca2 +-bind
Ca2 +-binding protein (HRCBP), the surface Ca2 +-removal system consisting of the
as well as the SR Ca2 +-removal system represented by SERCA2 Ca2 +-ATPase un
deficiency in the Dp427 isoform of dystrophin on the dystrophin-associated gl
extracellular matrix component laminin (LAM) and the actin membrane cytoskeleto
increase in the cytosolic Ca2 +-levels and the decrease in luminal SR Ca2 +-buffer4. Discussion
Cardiomyopathy is a serious complication associated
with DMD [16,17]. Approximately 20% of deaths in X-
linked muscular dystrophy are due to cardiac involvement
[2]. Previous investigations into the degenerative pathways
leading to skeletal muscle necrosis strongly indicate that,
following sarcolemmal micro-rupturing, downstream alter-
ation in Ca2 +-cycling plays a major role in muscular
dystrophy [9,12–14]. Thus, although the primary abnor-
mality in the full-length dystrophin isoform Dp427 is
clearly the underlying cause for DMD [4], abnormal
Ca2 +-fluxes represent the key pathophysiological process
leading to the end-stage muscle wasting mechanism [8]. In
analogy, here we can show that deficiency in the cardiac
Dp427 protein also has an effect on Ca2 +-regulatory
elements involved in the excitation–contraction–relaxation
cycle of the heart. The fact that CSQ and SAR are
important luminal mediators between the energy-dependent
Ca2 +-uptake via Ca2 +-ATPase pump units and the Ca2 +-
efflux mechanism through the junctional ryanodine recep-
tor complex [29,30] makes the decreased abundance in the
dystrophic heart a significant finding. It is important to
stress that SR Ca2 +-binding proteins do not simply repre-
sent ion traps that facilitate the Ca2 + re-uptake against a
less steep gradient and drastically increase the luminal
Ca2 +-storage capacity, but were also shown to act as
endogenous regulators of SR Ca2 +-channels [31]. Hence,is a diagram of the major Ca2 +-regulatory elements involved in cardiac
erse-tubular (TT) a1C-dihydropyridine receptor (DHPR) Ca
2 +-channel and
ase channel (CRC), whose signal transduction mechanism is mediated by a
ing proteins sarcalumenin (SAR), calsequestrin (CSQ) and the histidine-rich
Na+/Ca2 +-exchanger (NCX) and the plasmalemma Ca2 +-ATPase (PMCA),
its and its regulator subunit phospholamban (PLB). The effect of a primary
ycoprotein complex (DAGC) of the cardiac surface membrane (SM), the
n (AMC) in the cytosol (CY) is indicated. The proposed pathophysiological
ing capacity are marked by solid arrows.
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CSQ and SAR may trigger a considerable disturbance of
the Ca2 +-cycling apparatus in the dystrophic heart, as
outlined in Fig. 5.
For bulk Ca2 +-ion buffering, CSQ clusters are the most
important luminal binding protein [32]. Although CSQ has a
relatively low affinity for Ca2 +-ions with a dissociation
constant of approximately 1 mM, the binding capacity of
over 40 Ca2 +-ions per monomeric protein chain establishes
CSQ as a high-capacity ion-binding protein [32,33]. The
reduced expression in the dystrophic heart might have an
effect on the overall Ca2 +-binding capacity of the cardiac
SR, since CSQ oligomers exhibit positive co-operativity
with respect to high capacity Ca2 +-binding [34]. Protein–
protein interactions seem to play a central role in regulating
luminal SR Ca2 +-levels. Since the luminal Ca2 +-concentra-
tion has a considerable influence on Ca2 +-release channel
opening, CSQ clustering probably directly modifies Ca2 +-
flux rates from the SR lumen [31]. Reduced CSQ expres-
sion, in conjunction with the recently reported decrease in
the Ca2 +-release channel in the mdx heart [35], indicates
that both Ca2 +-storage and Ca2 +-release are impaired in the
dystrophic heart.
Increased expression of HRCBP [36] probably represents
a compensatory mechanism [37]. In analogy to CSQ, cycles
of phosphorylation and dephosphorylation of HRCBP are
also implicated in modulating the activity of the junctional
ryanodine receptor Ca2 +-release channel complex [38]. Up-
regulation of this endogenous physiological regulator of
Ca2 +-fluxing might counteract some of the loss in other
Ca2 +-regulatory elements. In contrast, the reduced SAR
expression may trigger impaired luminal ion transport.
SAR co-localises with the SR Ca2 +-ATPase [29] indicating
a mediating role between Ca2 +-uptake via the longitudinal
tubules/terminal cisternae region and the Ca2 +-storage/re-
lease sites close to the junctional SR membrane. Hence,
reduction in SAR most likely plays a major role in the
progressive molecular pathogenesis of the cardiac involve-
ment in X-linked muscular dystrophy.
Although major differences exist in the fine regulation of
excitation–contraction coupling and fibre relaxation be-
tween skeletal muscle and heart [39], abnormal Ca2 +-
cycling might underlie dystrophic changes in both types
of muscle. It is clearly established that cardiac excitation–
contraction coupling is based on a Ca2 +-induced Ca2 +-
release mechanism [40], while skeletal muscle signal trans-
duction at the triadic junction is mediated by direct receptor
coupling [41]. Muscle relaxation in fast-twitching skeletal
muscle fibres involves almost exclusively sarcolipin-regu-
lated SERCA1 units of the SR Ca2 +-ATPase [42]. In
contrast, cardiac relaxation is initiated by the activity of
the surface Na+/Ca2 +-exchanger and phospolamban-regu-
lated SERCA2 complexes of the SR [42]. Hence, individual
steps in Ca2 +-mediated fibre degeneration might show
differences between the heart and skeletal muscles, but the
general effect of elevated cytosolic Ca2 +-levels and de-creased luminal Ca2 +-buffering appears to be similar in
both classes of muscle tissue.Acknowledgements
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